GlaxoSmithKline Pharmaceuticals Limited — Investor Meet, 15-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

GlaxoSmithKline Pharmaceuticals reported 9% revenue growth to INR 3,723 Cr, led by volume-driven 8% growth in general medicines and 35% in specialty segments. EBITDA surged 30% to INR 1,169 Cr with margins at 31%. PAT rose 32%, supported by strong cash flow. Pediatric vaccines grew 12%, aided by Shingrix. Key brands like Augmentin hold market leadership despite a soft acute segment. Management is focused on sustained volume growth, margin expansion, and launching oncology therapies Jemperli and Zejula. Digital doctor engagement now covers 2.75 lakh HCPs, supporting core and innovative therapy expansion.